Foghorn Therapeutics Inc.Foghorn Therapeutics Inc. - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

The report of Foghorn Therapeutics Inc. incorporates intelligence from across the web as well as from public filings by Foghorn Therapeutics Inc.. This ESG score for Foghorn Therapeutics Inc. indicates its transparency towards the United Nations Sustainable Development Goals. This Disclosure rating includes seventeen United Nations Sustainable Development Goals including: 'Affordable & Clean Energy', 'Decent Work & Economic Growth' and 'Life below Water'.

Foghorn Therapeutics Inc. in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.0; made up of an environmental score of 3.2, social score of 3.2 and governance score of 2.7.

SDG Transparency Score for Foghorn Therapeutics Inc. 

3.0

Low Impact
0 - 3
Medium
4 - 6
High
7 - 10
Last Score Update: 2023-07-01
What drives the score for Foghorn Therapeutics Inc. 
3.2

Environmental

3.2

Social

2.7

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Novartis AG
9.2
High
2Daiichi Sankyo Co Ltd
8.9
High
.........
1760Protagenic Therapeutics Inc
3.1
Medium
1760Vcanbio Cell & Gene Engineering Corp Ltd
3.1
Medium
1800Foghorn Therapeutics Inc.
3.0
Medium
1800Allergan plc
3.0
Medium
1800Aptevo Therapeutics Inc
3.0
Medium
.........
2749Xynomic Pharmaceuticals Holdings Inc
0.0
Low
2749Zyden Gentec Ltd
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Foghorn Therapeutics Inc. have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. report the average age of the workforce?

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. disclose cybersecurity risks?

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. offer flexible work?

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. conduct supply chain audits?

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. disclose water use targets?

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Foghorn Therapeutics Inc. have a product recall in the last two years?

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. disclose incidents of discrimination?

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Foghorn Therapeutics Inc. issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. disclose parental leave metrics?

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Foghorn Therapeutics Inc. involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. disclose its waste policy?

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. report according to TCFD requirements?

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. disclose energy use targets?

LockedSign up for free to unlock

Does Foghorn Therapeutics Inc. disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Foghorn Therapeutics Inc. have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Foghorn Therapeutics Inc.
These potential risks are based on the size, segment and geographies of the company.

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. Foghorn Therapeutics Inc. has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel therapeutics based on disruptors of a specified transcription factor target. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Sorry!

Failed to process!